RoosterBio and Sartorius collaborate to scale up cell and gene therapy manufacturing
pharmafile | January 15, 2021 | News story | Medical Communications | RoosterBio, Sartorius
RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, has announced a collaboration with life sciences company Sartorius.
The aim of the collaboration is to advance the scale-up of hMSC manufacturing for regenerative medicine by significantly reducing process development efforts, industrialising the supply chain, and accelerating the development and commercialisation of cell-based regenerative cures.
RoosterBio and Sartorius will create a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems, alongside Germany-based Sartorius’ single use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing.
The joint effort of both companies will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that will allow product developers to significantly speed up their development timelines.
RoosterBio’s CEO, Margot Connor, said: “For truly robust and standardised production in the field, a highly controlled manufacturing strategy is needed, with the implementation of automation, process monitoring and control to increase batch scale, consistency and efficiency.
“This collaboration is well-positioned to accomplish the clinical scale requirements of regenerative medicine product developers while laying foundation for true commercial-scale manufacturing.”
Hugo de Wit, Head of Advanced Therapies at Sartorius, added: “With the combination of technologies and tools of RoosterBio and Sartorius we support our customers to develop stem cell and therapies faster, better and more cost-efficient.
“Scalability is key in commercial manufacturing and this cooperation will help to meet the requirements of our customers even better.”
Both companies intend to use the data from the collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.
Darcy Jimenez
Related Content
Sartorius doubles production capacity in UK with new facility
Pharmaceutical and laboratory equipment provider Sartorius has expanded operations at its Stonehouse site in Gloucestershire …
Sales of bioreactors in Asia boost Sartorius
Processing equipment company Sartorius posted a healthy 6% increase in sales in the first half …
